Investors & Media

Ionis’ antisense therapies to be featured at the American Heart Association (AHA) Scientific Sessions 2021

– New data to be presented from multiple ascending dose study for Ionis’ novel antisense medicine targeting PCSK9 – Data on the effect of olezarsen on a variety of lipoprotein fractions in patients with hypertriglyceridemia to be presented – Ionis to host symposium on lessening the disproportionate

Read more
You are now leaving to visit